Article
The AACE highlighted a number of studies on a wide range of endocrinology topics from adrenal disorders to metabolic bone disease.
Abstract no. 201
Continuous Glucose Monitoring Improved Detection of Hypoglycemia in Hospitalized Patients
18
Page:
Margaret Ryan, MD, Vincent Savarese, MD, Brian Hipszer, PhD, Mary Kate McCullen, MD, et al.
Authors:
To determine whether the use of continuous, glucose monitoring (CGM) in hospitalized patients at high risk for hypoglycemia led to improved detection of
Purpose: “
hypoglycemic events.”
The study focuses on 14 patients “with a documented hypoglycemic event during their hospitalization.” Researchers collected continuous glucose monitoring data by inserting a
CGMS
®
i
Pro
TM
Continuos Glucose Recorder on each patient “until either their anticipated day of discharge or completion of 144 hours of CGM data collection.
Point-of-care (POC) and laboratory blood glucose levels were monitored as per usual hospital protocol throughout the study.”
Results: ” “Results demonstrated that CGM use in high risk hospitalized patients detected hypoglycemic episodes earlier and more often than POC testing alone.” Researchers concluded that “earlier detection of hypoglycemia and prevention of hypoglycemia related complications.”
Abstract no. 260
Insulin Pump Therapy and Continuous Glucose Monitoring System (CGMS) in Patients with Type 1 Diabetes Mellitus
50
Page:
Banshi Damodarlal Saboo, MD, Phatak S.R., Shashank Joshi, MD, FACP, FRCP, FACE, Brahmkshatriya Priyanka P., et al.
Authors:
The use of insulin pumps has become “increasingly popular over the past several years.” While the use of insulin pumps can be beneficial, it also has certain limitations including: “high costs, round the clock use, and an increased need of monitoring to avoid hypoglycemia and ketoacidosis.” Researchers sought to observe the use of insulin pumps in conjunction with CGMS (continuous, automatic, monitoring of glucose in the subcutaneous tissue) to evaluate the effectiveness in properly delivering measurements of glucose levels continuously.
Purpose:
Researchers concluded that “reduction in the costs and further improvements in technology would ensure more widespread use of this potential method of continuously monitoring glucose levels.”
Results:
Abstract no. 272
Major Discrepancy in Fingerstick Capillary Glucose Readings in a Patient with Finger Edema
56
Page:
Ankur Gupta, MD, Marina M. Charitou.
Authors:
Researchers highlight a “case of finger edema leading to markedly inaccurate fingerstick glucose readings.”
Purpose:
Results: The study focused on a case involving an 80-year-old woman with diabetes mellitus type 2, who was admitted for management of atrial fibrillation.
The patient had mild edema on her finger tips.
Finger-stick glucose readings taken during her hospital stay varied from 24 to 586 mg/dl. The patient would come to experience an episode that left her unresponsive. “On the day of evaluation, the patient’s FS glucose reading before dinner was 245 mg/dl. At 10:17 pm, initial FS glucose reading was
46 and repeat was 231 mg/dl. At 1:45 am, the patient was found to be unresponsive. The initial FS glucose reading at that time was 426 mg/dl. The patient’s repeat FS glucose readings within several minutes of each other were 24, 204, and 272 mg/dl. The patient was not assumed to be hypoglycemic and all measures were taken to resuscitate the patient but the patient remained unresponsive. The patient was given 3 ampules of 50% dextrose and her mental status returned to her baseline. Her subsequent FS readings were 586 and 460 mg/dl with serum glucose 392 mg/dl tested at same time. Doctors determined there was no malfunction in the equipment used, and tried alternate site testing where no edema was present, i.e. the palm. “Alternate site testing at the palm correlated well with venous blood glucose testing.”
The AACE highlighted a number of studies on a wide range of endocrinology topics from adrenal disorders to metabolic bone disease. Listed below are just a few of the interesting items featured under the diabetes category, the following focus on continuous glucose monitoring studies:
FDA Approves Crinecerfont for Congenital Adrenal Hyperplasia